Myeloproliferative Neoplasm
Conditions
Keywords
Anemia
Brief summary
This study assesses the potential of using a TGFβ receptor inhibitor for the treatment of anemic patients with myeloproliferative neoplasms. TGFβ signaling is known to be abnormally high in patients with myeloproliferative neoplasms and it is thought that abnormal TGFβ signals cause many of the problems with blood cell formation in these diseases. The study design allows all patients to receive the study drug, vactosertib. The dose of vactosertib is individualized within a pre-set range based upon its effectiveness and tolerability. A total of up to 37 patients will be treated.
Detailed description
This is a two-tiered multi arm Phase 2 trial of vactosertib (TEW-7197) for the treatment of anemia in Ph-neg MPNs. Both tiers use a rule-based, accelerated dose escalation scheme to efficiently assess the potential of vactosertib to safely and effectively treat anemic patients with Ph-neg MPNs. The first tier of this trial (Tier 1) is an intra-patient dose finding study in 12 patients that uses a low starting dose of vactosertib for all patients. Treatment dose is escalated according to prospectively-defined rules, and a toxicity and treatment effect algorithm during the period of 16 weeks (4 treatment cycles). If pre-established efficacy and safety endpoints are met, then Tier 1 of the study will be followed by a Tier 2 expansion study with an additional 25 patients for a period of 24 weeks (6 treatment cycles). Vactosertib will be administered concurrently with the patient's current treatment (if any). Prior to enrollment, patients must be on a stable dose of their current therapy for 3 months prior to entering the study. Supportive care measures including packed red blood cell (PRBC) transfusions for HGB \<7g/dL, or symptomatic anemia, will be permitted. Administration of erythropoiesis stimulating agents (ESAs), however, will not be permitted on the trial (patients recruited would have serum EPO \>125 U/L above which the benefit of ESAs is not supported).
Interventions
DRUGVactosertib
50 mg BID This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
Sponsors
Weill Medical College of Cornell University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is an intra-patient dose finding study which starts with low dose of vactosertib.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients who meet the WHO 2016 criteria for a Ph-neg MPN (including PV, ET, MF, MDS/MPN, MPN-U). * Patients with MF must have DIPSS+ Intermediate or High-risk MF (primary of post-PV/ET). * For patients receiving cytoreductive therapy, they should be on a stable dose of current cytoreductive therapy for at least 3 months prior to C1D1. * Anemia as defined by HGB \< 10 g/dL, or transfusion of ≥ 2 packed red blood cell (PRBC) unit within the past 4 weeks with HGB ≤8.5g/dL. * Ineligible, unsuitable or refractoriness to ESA therapy defined as any of the following: * Serum erythropoietin (EPO) \>125 U/L. * Proven ESA unsuitability is defined by history of any of the following: * Loss of erythroid hematologic improvement while receiving stable or increased ESA dose; or * ESA-attributed toxicity that, in the treating physician's opinion, makes ESA therapy unsuitable for subject. * ESA refractoriness defined by lack of erythroid hematologic improvement to ESA:27 * Less than 1.5 g/dL increase in hemoglobin after at least 6 weeks of ESA therapy; or * Ongoing transfusion dependence that has not been reduced by \> 4U over an 8-week period compared to ESA pre-treatment 8 weeks. * Acceptable Cardiovascular status
Exclusion criteria
* Any other serious medical condition which in the Investigator's opinion would preclude safe participation in the study. * Patients with history of TIA or stroke within the past 12 months are excluded. * Female subjects who are breastfeeding, or intend to breastfeed, during the study or in the 30 days following the last dose of study drug are excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identify the Maximum Tolerated Dose (MTD) of Vactosertib in Patients With MPN Enrolled on Tier 2 | baseline to week 12 | Identify the Maximum Tolerated Dose (MTD) of vactosertib defined as the highest dose which does not meet the Tier 2 stopping rule. The tier 2 stopping rule is triggered if any patient experiences a Grade 5 dose limiting toxicity within the first 12 weeks of starting vactosertib or if more than five patients experience a dose limiting toxicity at any dose within the first 12 weeks on study. |
| Identify Dose Limiting Toxicities (DLTs) in Patients With MPN Enrolled on Tier 1 | Baseline to week 12 | Identify the incidence of dose limiting toxicity (DLT) within the first 12 weeks which are defined as: 1. Any non-hematologic grade ≥3 toxicity except for nausea, vomiting or diarrhea lasting 3 days or less 2. Any grade 4 neutropenia of any duration 3. Any grade ≥3 neutropenia that has not recovered to grade ≥2 within 7 days of onset 4. Any grade ≥3 febrile neutropenia 5. Any grade ≥3 thrombocytopenia associated with clinically significant bleeding or requiring platelet transfusion |
| Identify the Maximum Tolerated Dose (MTD) of Vactosertib in Patients With MPN Enrolled on Tier 1 | Baseline to week 12 | Identify the Maximum Tolerated Dose (MTD) of vactosertib defined as the highest dose which does not meet the Tier 1 stopping rule. The tier 1 stopping rule is triggered if any patient experiences a Grade 5 dose limiting toxicity within the first 12 weeks of starting vactosertib or if more than five patients experience a dose limiting toxicity at any dose within the first 12 weeks on study. |
| Number of Tier 2 Patients Who Have Achieved Erythropoietic Response as Defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) Criteria | baseline to week 16 | Number of patients who achieve an erythropoietic response defined by: 1. HGB increase of 1.5g/dL compared to baseline hemoglobin; 2. Reduction in PRBC transfusion rate to ≤ 50% of pre-treatment transfusion rate; or 3. Reduction in PRBC transfusions by ≥ 4 Units over an 8-week period. |
| Number of Tier 2 Patients Who Have Achieved Clinical Response in Symptoms as Defined by International Working Group (IWG) Criteria | baseline to week 16 | Number of patients who have achieved clinical response defined by a reduction in Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) total score by ≥ 50% compared to pretreatment score |
| Number of Tier 2 Patients Who Have Achieved Splenic Response in Symptoms as Defined by International Working Group (IWG) Criteria | baseline to week 16 | Number of patients who have achieved splenic response defined by: 1. Non-palpable spleen when baseline spleen size was 5-10 cm below left costal margin; 2. At least 50% reduction in spleen size when baseline spleen is \> 10 cm below left costal margin 3. At least 35% reduction in spleen size as assessed by US, CT or MRI. |
| Identify Dose Limiting Toxicities (DLTs) in Patients With MPN Enrolled on Tier 2 | baseline to week 12 | Identify the number of dose limiting toxicities (DLT) within the first 12 weeks which are defined as: 1. Any non-hematologic grade ≥3 toxicity except for nausea, vomiting or diarrhea lasting 3 days or less 2. Any grade 4 neutropenia of any duration 3. Any grade ≥3 neutropenia that has not recovered to grade ≥2 within 7 days of onset 4. Any grade ≥3 febrile neutropenia 5. Any grade ≥3 thrombocytopenia associated with clinically significant bleeding or requiring platelet transfusion |
| Identify the Safest, Minimally Effective Starting Dose Level for Patients on Tier 1 | Baseline to week 16 | The safest minimally effective dose is defined as the lowest dose level for which no dose limiting toxicity (DLT) was observed in Tier 1 AND the lowest dose level for which at least one of the 12 subjects enrolled on Tier 1 meet Criteria for Clinical Benefit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients in Which a Molecular Response is Seen | 16 weeks | Number of patients in which a molecular response is seen. Molecular response is defined by a decrease in VAF of MPN-driver mutations (eg. JAK2, CALR, and MPL allelic ratio) in blood and/or bone marrow cells |
| Number of Patients in Which a Pharmacodynamic Response is Seen | 16 weeks | A pharmacodynamic response is defined as any of the following: 1. Reduced immunohistochemical staining for SMAD2/3 phosphorylation in bone marrow biopsy sections. 2. Reduced mean fluorescence intensity of SMAD2/3 phosphorylation staining in peripheral blood hematopoietic stem and progenitor cells (HSPCs) or mature progeny as assessed by flow cytometry. 3. Reduced mean fluorescence intensity of SMAD2/3 phosphorylation staining in bone marrow hematopoietic stem and progenitor cells (HSPCs) or mature progeny as assessed by flow cytometry. |
| Number of Patients Who Have Experienced Any of the Following: Hematologic Toxicities, Infections, Disease Progression, and Thrombosis Events | baseline to 16 weeks | — |
| Overall Survival Defined as the Amount of Time a Patient is Alive After Starting Study Treatment | Week 1 Day 1 to 6 months post treatment discontinuation. This collection period for both subjects on study was over an average duration of 54 weeks. | The overall survival range describes the average length of time subjects were followed for survival |
| Progression Free Survival Defined as the Duration of Time From Start of Treatment to Time of Progression | Week 1 Day 1 to 6 months post treatment discontinuation | — |
| Number of Patients in Which a Histological Response is Seen | 16 weeks | Histological response is defined by reduction of any amount in grade of bone marrow fibrosis by histopathologic assessment at 16 weeks. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| All Participants Vactosertib intra-patient dose finding cohort.
Vactosertib This drug is a TG-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs. | 2 |
| Total | 2 |
Baseline characteristics
| Characteristic | All Participants |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 2 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 1 Participants |
| Sex: Female, Male Female | 1 Participants |
| Sex: Female, Male Male | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 2 | 0 / 2 | 0 / 2 | 0 / 2 | 0 / 0 | 0 / 2 |
| other Total, other adverse events | 2 / 2 | 2 / 2 | 2 / 2 | 2 / 2 | 0 / 0 | 2 / 2 |
| serious Total, serious adverse events | 0 / 2 | 0 / 2 | 0 / 2 | 0 / 2 | 0 / 0 | 0 / 2 |
Outcome results
Primary
Identify Dose Limiting Toxicities (DLTs) in Patients With MPN Enrolled on Tier 1
Identify the incidence of dose limiting toxicity (DLT) within the first 12 weeks which are defined as: 1. Any non-hematologic grade ≥3 toxicity except for nausea, vomiting or diarrhea lasting 3 days or less 2. Any grade 4 neutropenia of any duration 3. Any grade ≥3 neutropenia that has not recovered to grade ≥2 within 7 days of onset 4. Any grade ≥3 febrile neutropenia 5. Any grade ≥3 thrombocytopenia associated with clinically significant bleeding or requiring platelet transfusion
Time frame: Baseline to week 12
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Participants | Identify Dose Limiting Toxicities (DLTs) in Patients With MPN Enrolled on Tier 1 | 0 Count of DLTs |
| Tier 1: Vactosertib 100 mg BID | Identify Dose Limiting Toxicities (DLTs) in Patients With MPN Enrolled on Tier 1 | 0 Count of DLTs |
| Tier 1: Vactosertib 150 mg BID | Identify Dose Limiting Toxicities (DLTs) in Patients With MPN Enrolled on Tier 1 | 0 Count of DLTs |
| Tier 1: Vactosertib 200mg BID | Identify Dose Limiting Toxicities (DLTs) in Patients With MPN Enrolled on Tier 1 | 0 Count of DLTs |
Primary
Identify Dose Limiting Toxicities (DLTs) in Patients With MPN Enrolled on Tier 2
Identify the number of dose limiting toxicities (DLT) within the first 12 weeks which are defined as: 1. Any non-hematologic grade ≥3 toxicity except for nausea, vomiting or diarrhea lasting 3 days or less 2. Any grade 4 neutropenia of any duration 3. Any grade ≥3 neutropenia that has not recovered to grade ≥2 within 7 days of onset 4. Any grade ≥3 febrile neutropenia 5. Any grade ≥3 thrombocytopenia associated with clinically significant bleeding or requiring platelet transfusion
Time frame: baseline to week 12
Population: No subjects went on to the Tier 2 portion of the study
Primary
Identify the Maximum Tolerated Dose (MTD) of Vactosertib in Patients With MPN Enrolled on Tier 1
Identify the Maximum Tolerated Dose (MTD) of vactosertib defined as the highest dose which does not meet the Tier 1 stopping rule. The tier 1 stopping rule is triggered if any patient experiences a Grade 5 dose limiting toxicity within the first 12 weeks of starting vactosertib or if more than five patients experience a dose limiting toxicity at any dose within the first 12 weeks on study.
Time frame: Baseline to week 12
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Participants | Identify the Maximum Tolerated Dose (MTD) of Vactosertib in Patients With MPN Enrolled on Tier 1 | 200 mg |
Primary
Identify the Maximum Tolerated Dose (MTD) of Vactosertib in Patients With MPN Enrolled on Tier 2
Identify the Maximum Tolerated Dose (MTD) of vactosertib defined as the highest dose which does not meet the Tier 2 stopping rule. The tier 2 stopping rule is triggered if any patient experiences a Grade 5 dose limiting toxicity within the first 12 weeks of starting vactosertib or if more than five patients experience a dose limiting toxicity at any dose within the first 12 weeks on study.
Time frame: baseline to week 12
Population: No subjects went on to the Tier 2 portion of the study
Primary
Identify the Safest, Minimally Effective Starting Dose Level for Patients on Tier 1
The safest minimally effective dose is defined as the lowest dose level for which no dose limiting toxicity (DLT) was observed in Tier 1 AND the lowest dose level for which at least one of the 12 subjects enrolled on Tier 1 meet Criteria for Clinical Benefit
Time frame: Baseline to week 16
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Participants | Identify the Safest, Minimally Effective Starting Dose Level for Patients on Tier 1 | 50 mg |
Primary
Number of Tier 2 Patients Who Have Achieved Clinical Response in Symptoms as Defined by International Working Group (IWG) Criteria
Number of patients who have achieved clinical response defined by a reduction in Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) total score by ≥ 50% compared to pretreatment score
Time frame: baseline to week 16
Population: No subjects went on to the Tier 2 portion of the study
Primary
Number of Tier 2 Patients Who Have Achieved Erythropoietic Response as Defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) Criteria
Number of patients who achieve an erythropoietic response defined by: 1. HGB increase of 1.5g/dL compared to baseline hemoglobin; 2. Reduction in PRBC transfusion rate to ≤ 50% of pre-treatment transfusion rate; or 3. Reduction in PRBC transfusions by ≥ 4 Units over an 8-week period.
Time frame: baseline to week 16
Population: No subjects went on to the Tier 2 portion of the study
Primary
Number of Tier 2 Patients Who Have Achieved Splenic Response in Symptoms as Defined by International Working Group (IWG) Criteria
Number of patients who have achieved splenic response defined by: 1. Non-palpable spleen when baseline spleen size was 5-10 cm below left costal margin; 2. At least 50% reduction in spleen size when baseline spleen is \> 10 cm below left costal margin 3. At least 35% reduction in spleen size as assessed by US, CT or MRI.
Time frame: baseline to week 16
Population: No subjects went on to the Tier 2 portion of the study
Secondary
Number of Patients in Which a Histological Response is Seen
Histological response is defined by reduction of any amount in grade of bone marrow fibrosis by histopathologic assessment at 16 weeks.
Time frame: 16 weeks
Population: 0 subjects were analyzed for Tier 1 subjects taking 50mg, 100mg, and 150mg of Vactosertib because no participants were taking those doses at 16 weeks. 0 subjects were analyzed in Tier 2 because no subjects were in Tier 2 at 16 weeks.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| All Participants | Number of Patients in Which a Histological Response is Seen | 0 Participants |
| Tier 1: Vactosertib 100 mg BID | Number of Patients in Which a Histological Response is Seen | 0 Participants |
| Tier 1: Vactosertib 150 mg BID | Number of Patients in Which a Histological Response is Seen | 0 Participants |
| Tier 1: Vactosertib 200mg BID | Number of Patients in Which a Histological Response is Seen | 0 Participants |
| Tier 2: Vactosertib | Number of Patients in Which a Histological Response is Seen | 0 Participants |
Secondary
Number of Patients in Which a Molecular Response is Seen
Number of patients in which a molecular response is seen. Molecular response is defined by a decrease in VAF of MPN-driver mutations (eg. JAK2, CALR, and MPL allelic ratio) in blood and/or bone marrow cells
Time frame: 16 weeks
Population: 0 subjects were analyzed for Tier 1 subjects taking 50mg, 100mg, and 150mg of Vactosertib because no participants were taking those doses at 16 weeks. 0 subjects were analyzed in Tier 2 because no subjects were in Tier 2 at 16 weeks.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| All Participants | Number of Patients in Which a Molecular Response is Seen | 0 Participants |
| Tier 1: Vactosertib 100 mg BID | Number of Patients in Which a Molecular Response is Seen | 0 Participants |
| Tier 1: Vactosertib 150 mg BID | Number of Patients in Which a Molecular Response is Seen | 0 Participants |
| Tier 1: Vactosertib 200mg BID | Number of Patients in Which a Molecular Response is Seen | 1 Participants |
| Tier 2: Vactosertib | Number of Patients in Which a Molecular Response is Seen | 0 Participants |
Secondary
Number of Patients in Which a Pharmacodynamic Response is Seen
A pharmacodynamic response is defined as any of the following: 1. Reduced immunohistochemical staining for SMAD2/3 phosphorylation in bone marrow biopsy sections. 2. Reduced mean fluorescence intensity of SMAD2/3 phosphorylation staining in peripheral blood hematopoietic stem and progenitor cells (HSPCs) or mature progeny as assessed by flow cytometry. 3. Reduced mean fluorescence intensity of SMAD2/3 phosphorylation staining in bone marrow hematopoietic stem and progenitor cells (HSPCs) or mature progeny as assessed by flow cytometry.
Time frame: 16 weeks
Population: 0 subjects were analyzed for Tier 1 subjects taking 50mg, 100mg, and 150mg of Vactosertib because no participants were taking those doses at 16 weeks. 0 subjects were analyzed in Tier 2 because no subjects were in Tier 2 at 16 weeks.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| All Participants | Number of Patients in Which a Pharmacodynamic Response is Seen | 0 Participants |
| Tier 1: Vactosertib 100 mg BID | Number of Patients in Which a Pharmacodynamic Response is Seen | 0 Participants |
| Tier 1: Vactosertib 150 mg BID | Number of Patients in Which a Pharmacodynamic Response is Seen | 0 Participants |
| Tier 1: Vactosertib 200mg BID | Number of Patients in Which a Pharmacodynamic Response is Seen | 1 Participants |
| Tier 2: Vactosertib | Number of Patients in Which a Pharmacodynamic Response is Seen | 0 Participants |
Secondary
Number of Patients Who Have Experienced Any of the Following: Hematologic Toxicities, Infections, Disease Progression, and Thrombosis Events
Time frame: baseline to 16 weeks
Population: No subjects enrolled on Tier 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| All Participants | Number of Patients Who Have Experienced Any of the Following: Hematologic Toxicities, Infections, Disease Progression, and Thrombosis Events | 0 Participants |
| Tier 1: Vactosertib 100 mg BID | Number of Patients Who Have Experienced Any of the Following: Hematologic Toxicities, Infections, Disease Progression, and Thrombosis Events | 0 Participants |
| Tier 1: Vactosertib 150 mg BID | Number of Patients Who Have Experienced Any of the Following: Hematologic Toxicities, Infections, Disease Progression, and Thrombosis Events | 1 Participants |
| Tier 1: Vactosertib 200mg BID | Number of Patients Who Have Experienced Any of the Following: Hematologic Toxicities, Infections, Disease Progression, and Thrombosis Events | 2 Participants |
| Tier 2: Vactosertib | Number of Patients Who Have Experienced Any of the Following: Hematologic Toxicities, Infections, Disease Progression, and Thrombosis Events | 0 Participants |
Secondary
Overall Survival Defined as the Amount of Time a Patient is Alive After Starting Study Treatment
The overall survival range describes the average length of time subjects were followed for survival
Time frame: Week 1 Day 1 to 6 months post treatment discontinuation. This collection period for both subjects on study was over an average duration of 54 weeks.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| All Participants | Overall Survival Defined as the Amount of Time a Patient is Alive After Starting Study Treatment | 54 Weeks |
Secondary
Progression Free Survival Defined as the Duration of Time From Start of Treatment to Time of Progression
Time frame: Week 1 Day 1 to 6 months post treatment discontinuation
| Arm | Measure | Value (MEAN) |
|---|---|---|
| All Participants | Progression Free Survival Defined as the Duration of Time From Start of Treatment to Time of Progression | 25.5 Weeks |